ReviewClinical and translational radiation oncology2026
A systematic review of heterogeneity in clinical trial design for anal cancer radiotherapy-immunotherapy combinations.
Review in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localised anal squamous cell carcinoma (ASCC) is treated with radical chemoradiotherapy, which achieves durable disease control in most patients. However, treatment failure is stage-dependent, with approximately 25-30% of patients with locally advanced disease relapsing after treatment, supporting investigation of novel approaches such as radiotherapy-immunotherapy (RT-IO) combinations. Combining radiotherapy (RT) with immunotherapy (IO) shows promise, with multiple trials investigating different combinations. This review evaluates trial design for RT-IO trials in ASCC. A systematic review was conducted on PubMed, ClinicalTrials.gov, and EudraCT databases to identify interventional clinical trials evaluating RT combined with immune-modulating treatments for ASCC. The review was prospectively registered on PROSPERO (CRD42023384068). Information on trial design, patient selection, and treatment regimens was collected. Twelve trials were identified, with three reporting results for a combined total of 69 patients. Across all trials, 14 different IO regimens were used before, during, and after RT. Substantial heterogeneity was observed in patient selection, statistical design, chemotherapy, and RT regimens. Data on exploratory and translational analyses was available for six trials. No trials used biomarkers for enrolment, although INTERACT-ION used cHPV-DNA to guide post-induction treatment allocation. Full trial comparisons were hindered by protocol publication and commercial sensitivities. The diversity in IO regimens and timing relative to RT offers valuable data on RT-IO combinations for ASCC. However, heterogeneity in trial design and translational analysis will limit comparisons between trials. Two possible solutions to improve comparisons are a core minimal translational component and federated learning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.